Lawmaker wants to know how FDA can police drug ads after cutting its oversight workforce

Taking stock of the drug industry, from the lab to the medicine chest

May 27, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Alex Hogan/STAT STAT+ | Lawmaker wants to know how FDA can police drug ads after cutting its oversight workforce The concern over adequate FDA enforcement also comes as big drugmakers strike marketing deals with telehealth companies. By Ed Silverman STAT+ | What Baby KJ means for the CRISPR gene-editing industry The custom-built gene editing treatment for 6-month-old KJ Muldoon could not have come at a more welcome or jarring time for CRISPR-powered biomedicine. By Jason Mast RFK Jr. rolls back Covid vaccine recommendations for healthy children, pregnant people HHS Secretary Kennedy says Covid shots will no longer be recommended for healthy children and pregnant women. 'Overstepped his bounds,' says one expert. By Helen Branswell Courtesy Hilton Simmet STAT+ | At a major genome-editing summit, spotlight turns to the value of human life Earlier gatherings focused on gaining public acceptance for what scientists want to do with CRISPR. This meeting flipped that on its head. By Megan Molteni

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser